Home > Boards > US Listed > Biotechs >

Enanta Pharmaceuticals (ENTA)

ENTA RSS Feed
Add ENTA Price Alert      Hide Sticky   Hide Intro
Moderator: DewDiligence
Search This Board: 
Last Post: 11/28/2020 2:41:23 PM - Followers: 74 - Board type: Free - Posts Today: 0
ENTA
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
ENTA News: Annual Report (10-k) 11/25/2020 04:03:23 PM
ENTA News: Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2020 11/23/2020 04:01:00 PM
ENTA News: Enanta Pharmaceuticals to Present at Upcoming Investor Conferences 11/18/2020 07:02:00 AM
ENTA News: Enanta Pharmaceuticals to Host Conference Call on November 23 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal... 11/16/2020 07:02:00 AM
ENTA News: Statement of Changes in Beneficial Ownership (4) 11/12/2020 04:13:35 PM
PostSubject
#1915  Sticky Note ENTA new corporate slide set: DewDiligence 11/23/20 05:34:35 PM
#1921   ENTA’s enterprise value at the current share price—($42.90)—is DewDiligence 11/28/20 02:41:23 PM
#1920   ENTA’s fully-diluted* share count @9/30/20=23.3M—an increase of 0.6M DewDiligence 11/28/20 02:35:42 PM
#1919   ENTA’s pro forma cash @9/30/20=$445.3M—a decrease of DewDiligence 11/28/20 02:25:09 PM
#1918   ENTA never needs to raise capital, which makes DewDiligence 11/24/20 02:27:38 PM
#1917   Enanta price target lowered to $45 from $52 floblu14 11/24/20 11:14:55 AM
#1916   ENTA FY4Q20 CC transcript: DewDiligence 11/24/20 08:39:19 AM
#1915   ENTA new corporate slide set: DewDiligence 11/23/20 05:34:35 PM
#1914   ENTA FY4Q20* results—royalty_revenue=$23.6M—9/30/20_cash=$419M: DewDiligence 11/23/20 05:17:33 PM
#1913   Thoughts on this PR today? JK2016 11/23/20 04:26:52 PM
#1912   Enanta Pharmaceuticals to Present at Upcoming Investor Conferences floblu14 11/18/20 07:12:54 AM
#1911   Added to my position today. It’s unfathomable rwwine 11/16/20 09:20:39 PM
#1910   Enanta Pharmaceuticals to Host Conference Call on November floblu14 11/16/20 07:18:07 AM
#1909   ENTA investors are currently ascribing negative value to DewDiligence 11/08/20 08:04:10 PM
#1908   ABBV’s Mavyret_2020_guidance=$1.9B—implying ~$560M in 4Q20. (Source: Today’s 3Q2 DewDiligence 10/30/20 09:35:32 AM
#1907   ABBV 3Q20 Mavyret sales=$414M, +10% QoQ, -41% YoY: DewDiligence 10/30/20 09:33:00 AM
#1905   FWIW - floblu14 10/27/20 06:08:29 AM
#1904   Enanta Pharmaceuticals to Present at the 4th Annual floblu14 09/28/20 07:24:43 AM
#1903   ROTH Webinar - Enanta Pharmaceuticals (ENTA) - Registration floblu14 09/28/20 06:49:32 AM
#1902   Enanta management to meet virtually with Roth Capital floblu14 09/25/20 06:16:33 AM
#1901   What's with this share price? Yikes... JK2016 09/23/20 12:22:17 PM
#1900   ENTA new corporate slide set: DewDiligence 09/15/20 01:45:45 PM
#1899   ENANTA PHARMACEUTICALS INITIATES PHASE 1 CLINICAL STUDY OF floblu14 09/14/20 07:19:00 AM
#1898   If there’s a $100+ price target why DewDiligence 09/09/20 09:36:22 AM
#1897   Question. If there’s a $100+ price target JK2016 09/09/20 07:23:21 AM
#1896   Roth’s $104 price target is close to the DewDiligence 09/05/20 06:16:32 PM
#1895   Enanta resumed with a Buy at Roth Capital floblu14 09/05/20 05:35:16 PM
#1894   ENANTA PHARMACEUTICALS TO PARTICIPATE IN UPCOMING SEPTEMBER CONFERENCES floblu14 09/03/20 07:45:25 AM
#1893   ENANTA PHARMACEUTICALS PRESENTS NEW DATA FROM ITS HEPATITIS floblu14 08/28/20 07:07:43 AM
#1892   THANK YOU, DEW - floblu14 08/28/20 05:43:05 AM
#1891   Initiating coverage - ENTA - With a current floblu14 08/26/20 02:34:35 PM
#1890   ENTA’s EASL presentations (Aug 27-29): DewDiligence 08/20/20 09:26:51 AM
#1889   ENTA new corporate slide set: DewDiligence 08/04/20 09:03:40 PM
#1887   ENTA FY3Q20* results—royalty revenue=$18.6M—GAAP EPS=($0.71): DewDiligence 08/04/20 04:10:12 PM
#1886   ABBV’s 2Q20 Mavyret sales=$376M, -33% QoQ, -51% YoY—the DewDiligence 07/31/20 09:39:08 AM
#1885   ENTA new corporate slide set: vinmantoo 07/10/20 03:42:50 PM
#1884   ENTA new corporate slide set: DewDiligence 07/09/20 09:29:26 AM
#1883   ENTA starts/resumes two phase-1b HBV trials: DewDiligence 07/09/20 09:24:39 AM
#1882   ENTA new corporate slide set: DewDiligence 06/18/20 11:06:20 AM
#1881   ENTA’s CFO exercised and held ~$90K of stock today: DewDiligence 05/07/20 05:55:09 PM
#1880   …are you surprised that ENTA went up after DewDiligence 05/07/20 01:12:52 PM
#1879   Dew, are you surprised that ENTA went up vinmantoo 05/07/20 12:56:43 PM
#1878   ENTA FY2Q20 CC transcript: DewDiligence 05/07/20 10:14:26 AM
#1877   New corporate slide set: DewDiligence 05/06/20 05:57:37 PM
#1876   ENTA discontinues EDP-305 for PBC indication following phase-2 DewDiligence 05/06/20 04:16:39 PM
#1875   ENTA FY2Q20 results—royalty revenue=$27.6M—GAAP EPS=($0.30): DewDiligence 05/06/20 04:14:08 PM
#1874   Right! Thanks for noticing. DewDiligence 05/01/20 02:28:26 PM
#1873   On today’s 1Q20 CC, ABBV said about half 10nisman 05/01/20 02:17:01 PM
#1872   ABBV's 2020 HCV-sales guidance lowered to $2.3B (from DewDiligence 05/01/20 10:02:38 AM
#1870   ABBV 1Q20 results—HCV sales=$564M, -10.8% QoQ: DewDiligence 05/01/20 09:15:08 AM
#1869   Right. It shows how low Yahoo Finance has DewDiligence 04/28/20 08:44:22 PM
PostSubject
Consent Preferences